Callahan Advisors LLC Sells 1,564 Shares of Johnson & Johnson $JNJ

Key Points

• Callahan Advisors LLC sold 1,564 shares of Johnson & Johnson, reducing its stake to 123,488 shares, which represents 1.7% of its total holdings.
• Johnson & Johnson reported a quarterly earnings of $2.26 per share, with a total revenue of $24.02 billion and analysts expect an EPS of 10.58 for the current fiscal year.
• The company declared a quarterly dividend of $1.30 per share, set to be paid on December 9th, reflecting a yield of 2.7% and a payout ratio of 55.61%.

Callahan Advisors LLC reduced its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1.3% in the second quarter, according to its most recent filing with the SEC. The fund owned 123,488 shares of the company's stock after selling 1,564 shares during the quarter. Johnson & Johnson comprises approximately 1.7% of Callahan Advisors LLC's holdings, making the stock its 15th largest holding. Callahan Advisors LLC's holdings in Johnson & Johnson were worth $18,863,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. GFG Capital LLC bought a new position in shares of Johnson & Johnson in the 2nd quarter valued at about $35,000. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $47,000. 1248 Management LLC purchased a new position in shares of Johnson & Johnson in the 1st quarter worth approximately $48,000. von Borstel & Associates Inc. bought a new position in shares of Johnson & Johnson during the 1st quarter valued at approximately $49,000. Finally, Harvest Fund Management Co. Ltd bought a new position in Johnson & Johnson during the 1st quarter valued at about $52,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

NYSE JNJ opened at $193.27 on Friday. The company has a market cap of $465.45 billion, a PE ratio of 18.65, a P/E/G ratio of 2.26 and a beta of 0.40. The firm's 50 day moving average price is $180.49 and its 200-day moving average price is $164.80. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $194.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%.The company had revenue of $24.02 billion during the quarter. Sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson's payout ratio is 55.61%.

Wall Street Analyst Weigh In

JNJ has been the subject of several recent analyst reports. Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Guggenheim upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their target price for the stock from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $209.00 price target on shares of Johnson & Johnson in a research note on Friday, October 10th. Morgan Stanley set a $190.00 price objective on Johnson & Johnson in a research note on Wednesday. Finally, JPMorgan Chase & Co. lifted their target price on Johnson & Johnson from $185.00 to $200.00 and gave the company a "neutral" rating in a research report on Tuesday, September 16th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $199.59.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.